Unraveling the Dyslipidemic Landscape in Moyamoya Disease: OxLDL as a Key Biomarker

揭示烟雾病血脂异常的全貌:氧化低密度脂蛋白作为关键生物标志物

阅读:5

Abstract

AIMS: The pathogenic mechanisms of moyamoya disease (MMD) remain unrecognized. Although genetic predisposition and hemodynamic changes have been focused on, emerging evidence suggests dyslipidemia may also contribute to MMD. Here, we performed a comprehensive analysis of lipid profiles, aiming to elucidate potential mechanisms in MMD. METHODS: In this prospective case-control study, 222 MMD patients and 231 healthy controls (HCs) were enrolled. The comprehensive lipid profiling was performed, encompassing standard lipids, apolipoproteins, oxidized low-density lipoprotein (oxLDL), and small dense LDL (sdLDL). Statistical models of weighted quantile sum (WQS) and Bayesian kernel machine regression (BKMR) were applied to capture individual and joint lipid effects on MMD risk. RESULTS: Compared with HCs, MMD patients exhibited significantly higher oxLDL, sdLDL, and lipoprotein(a) (p < 0.05). OxLDL emerged as a robust independent risk factor for MMD (adjusted OR 1.146, 95% CI 1.102-1.210, p < 0.001). WQS analysis further identified oxLDL as the single greatest contributor to MMD risk, with additional support from BKMR showing marked synergistic interactions between oxLDL and homocysteine. CONCLUSIONS: The study revealed a comprehensive dyslipidemic landscape in MMD, highlighting oxLDL as a pivotal biomarker. The results underscored the significance of lipid metabolism in MMD pathogenesis, warranting further investigation to guide novel diagnostic and therapeutic strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。